Longeveron (LGVN) Set to Announce Earnings on Tuesday

Longeveron (NASDAQ:LGVN) is expected to issue its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of ($1.95) per share and revenue of $0.56 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Longeveron (NASDAQ:LGVN) last announced its earnings results on Wednesday, August 12th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.75) by $1.56. The firm had revenue of $0.29 million for the quarter, compared to the consensus estimate of $0.33 million. Longeveron had a negative return on equity of 223.19% and a negative net margin of 1,977.59%.

Longeveron Stock Up 0.3%

LGVN stock opened at $1.60 on Tuesday. The firm has a market cap of $5.12 million, a PE ratio of -0.16 and a beta of -0.19. The business has a 50 day moving average of $4.41 and a 200-day moving average of $6.69. Longeveron has a 12-month low of $1.31 and a 12-month high of $12.30.

Analyst Upgrades and Downgrades

LGVN has been the topic of several research analyst reports. Wall Street Zen cut Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings lowered Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $80.00.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes.

Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.